Canadian specialty pharmaceutical company Knight Therapeutics Inc. has committed $1 million to Genesys Ventures III, the third life sciences fund of Canadian venture capital firm Genesys Capital Management, Inc.

“We are pleased to support Genesys in their efforts to create innovative life sciences companies that will touch the lives of patients,” says Jonathan Ross Goodman, President and CEO of Knight.

Other disclosed fund investors include the Fonds de solidarité FTQ and HarbourVest Canada Growth Fund.

Genesys Capital, Fonds de solidarité FTQ, and HarbourVest Partners are members of the Canadian Venture Capital and Private Equity Association.